[S02DA03, antipyrine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Amphotericin B.]
[J01GA01, streptomycin, Amphotericin B may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Amphotericin B may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Amphotericin B may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Amphotericin B may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Amphotericin B.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be decreased when used in combination with Amphotericin B.]
[M01AX04, apazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Azapropazone.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Amphotericin B.]
[N05CD07, temazepam, Amphotericin B may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, Amphotericin B may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Amphotericin B may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Amphotericin B may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Tetracaine.]
[S03AA02, tetracycline, Amphotericin B may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftaroline fosamil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Thalidomide.]
[P02CA02, thiabendazole, Amphotericin B may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Amphotericin B may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Amphotericin B.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Amphotericin B.]
[G04BE06, moxisylyte, Amphotericin B may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Amphotericin B may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Amphotericin B may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Amphotericin B.]
[P01AB02, tinidazole, Amphotericin B may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Amphotericin B may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Amphotericin B may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolazoline.]
[V04CA01, tolbutamide, Amphotericin B may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Amphotericin B.]
[N02AX02, tramadol, Amphotericin B may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Amphotericin B.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Amphotericin B.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Amphotericin B.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Trichlormethiazide.]
[A16AX12, trientine, Amphotericin B may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Amphotericin B may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Amphotericin B.]
[R03BA07, mometasone, The risk or severity of hypokalemia can be increased when Mometasone is combined with Amphotericin B.]
[A03AA05, trimebutine, Trimebutine may decrease the nephrotoxic activities of Amphotericin B.]
[N03AC02, trimethadione, Trimethadione may decrease the nephrotoxic activities of Amphotericin B.]
[C02BA01, trimethaphan, Amphotericin B may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Amphotericin B.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Amphotericin B may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Amphotericin B may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Amphotericin B may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[S01AA28, vancomycin, Amphotericin B may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be decreased when used in combination with Amphotericin B.]
[B01AF01, rivaroxaban, Amphotericin B may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, Verapamil may decrease the nephrotoxic activities of Amphotericin B.]
[N06AX09, viloxazine, Amphotericin B may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[C04AX07, vincamine, Amphotericin B may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Amphotericin B.]
[B03BA01, vitamin B12, Amphotericin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Amphotericin B.]
[C03BA10, xipamide, Amphotericin B may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Amphotericin B.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Amphotericin B.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Amphotericin B.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Amphotericin B.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Tiludronic acid.]
[B06AC02, icatibant, Amphotericin B may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[A02BC04, rabeprazole, Amphotericin B may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Ibandronate.]
[V03AC02, deferiprone, Amphotericin B may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Amphotericin B may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Amphotericin B may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Amphotericin B may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Amphotericin B.]
[J02AC03, voriconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Voriconazole.]
[M01CB03, auranofin, Amphotericin B may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Amphotericin B.]
[B03XA04, peginesatide, Amphotericin B may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Amphotericin B may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Amphotericin B may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Amphotericin B may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Amphotericin B may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Amphotericin B.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Amphotericin B.]
[M03BX01, baclofen, Amphotericin B may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Amphotericin B may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Amphotericin B may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Amphotericin B may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Amphotericin B.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Amphotericin B.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin.]
[D02BA02, octinoxate, Amphotericin B may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Amphotericin B.]
[C08CA13, lercanidipine, Lercanidipine may decrease the nephrotoxic activities of Amphotericin B.]
[N03AX22, perampanel, The therapeutic efficacy of Perampanel can be decreased when used in combination with Amphotericin B.]
[V09IX04, fluorodeoxyglucose F18, Amphotericin B may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Amphotericin B.]
[V08CA11, gadofosveset, Amphotericin B may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Amphotericin B may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, Bencyclane may decrease the nephrotoxic activities of Amphotericin B.]
[A10BH04, alogliptin, Amphotericin B may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Amphotericin B may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, Amphotericin B may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Benzocaine.]
[L03AA12, ancestim, Amphotericin B may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Amphotericin B.]
[N04AC01, benztropine, Amphotericin B may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Benzydamine.]
[L01EE01, trametinib, Amphotericin B may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Amphotericin B may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Amphotericin B may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08EA02, bepridil, Bepridil may decrease the nephrotoxic activities of Amphotericin B.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Riociguat.]
[A10BJ03, lixisenatide, Amphotericin B may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Amphotericin B may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Amphotericin B may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Amphotericin B may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Amphotericin B.]
[J05AP08, sofosbuvir, Amphotericin B may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Amphotericin B.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.]
[C01CA27, droxidopa, Amphotericin B may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acebutolol.]
[N05CH03, tasimelteon, Amphotericin B may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Amphotericin B may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Amphotericin B may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Amphotericin B.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Amphotericin B.]
[V03AB34, fomepizole, Amphotericin B may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Amphotericin B may increase the hypotensive activities of Bethanidine.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Bezafibrate.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Amphotericin B.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.]
[V08AA01, diatrizoic acid, Amphotericin B may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Amphotericin B may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Dihydrostreptomycin.]
[S03AA06, gentamicin, Amphotericin B may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Amphotericin B.]
[B01AF03, edoxaban, Amphotericin B may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N02BE01, acetaminophen, Amphotericin B may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Amphotericin B may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Amphotericin B.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Adefovir dipivoxil.]
[M02AA25, aceclofenac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Amphotericin B.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Acipimox.]
[V03AB37, idarucizumab, Amphotericin B may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Trabectedin.]
[J02AC05, isavuconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Isavuconazole.]
[J05AF13, tenofovir alafenamide, Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Amphotericin B may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Amphotericin B may increase the hypotensive activities of Selexipag.]
[M04AB05, lesinurad, Amphotericin B may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Alminoprofen.]
[N03AX23, brivaracetam, The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Amphotericin B.]
[N05BA08, bromazepam, Amphotericin B may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Amphotericin B may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C08CA01, amlodipine, Amlodipine may decrease the nephrotoxic activities of Amphotericin B.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Bupivacaine.]
[C07AA19, bupranolol, Amphotericin B may increase the hypotensive activities of Bupranolol.]
[N05BE01, buspirone, Amphotericin B may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide.]
[M02AA03, clofezone, Amphotericin B may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Balsalazide.]
[A06AH05, naldemedine, Amphotericin B may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Amphotericin B may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Amphotericin B.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be decreased when used in combination with Amphotericin B.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Amphotericin B.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Amphotericin B may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Amphotericin B.]
[J05AF06, abacavir, Amphotericin B may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Amphotericin B may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Amphotericin B.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Amphotericin B.]
[J01MA23, delafloxacin, Amphotericin B may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[D01AC10, bifonazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bifonazole.]
[L01BC06, capecitabine, Amphotericin B may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Amphotericin B.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefprozil.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nesiritide.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Amphotericin B.]
[M01AB07, bumadizone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Bumadizone.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Capsaicin.]
[R06AX18, acrivastine, Amphotericin B may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Captopril.]
[L02BB05, apalutamide, Amphotericin B may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Amphotericin B may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Amphotericin B.]
[C07AG02, carvedilol, Carvedilol may decrease the nephrotoxic activities of Amphotericin B.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Amphotericin B.]
[N03AX24, cannabidiol, The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Amphotericin B.]
[L04AA37, baricitinib, Amphotericin B may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftibuten.]
[J01GB14, plazomicin, Amphotericin B may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Amphotericin B may increase the hypotensive activities of Celiprolol.]
[A16AX14, migalastat, Amphotericin B may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The therapeutic efficacy of Stiripentol can be decreased when used in combination with Amphotericin B.]
[S01GX12, cetirizine, Amphotericin B may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Amphotericin B may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Inotersen.]
[L01AD01, carmustine, Amphotericin B may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Amphotericin B is combined with Amifampridine.]
[A06AX05, prucalopride, Amphotericin B may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilazapril.]
[B01AC23, cilostazol, Amphotericin B may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ciprofibrate.]
[N06BA14, solriamfetol, Amphotericin B may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be decreased when used in combination with Amphotericin B.]
[N05BA09, clobazam, The therapeutic efficacy of Clobazam can be decreased when used in combination with Amphotericin B.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Amphotericin B.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ubidecarenone.]
[C09CA06, candesartan, Amphotericin B may increase the hypotensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Amphotericin B.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefaclor.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefazolin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Amphotericin B.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Amphotericin B.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Amphotericin B.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Amphotericin B.]
[C03BX03, cicletanine, Amphotericin B may increase the hypotensive activities of Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefuroxime.]
[N07XX11, pitolisant, Amphotericin B may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Cyclothiazide.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amphotericin B.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Amphotericin B.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Amphotericin B.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Amphotericin B.]
[N03AX25, cenobamate, The therapeutic efficacy of Cenobamate can be decreased when used in combination with Amphotericin B.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Givosiran.]
[M09AX08, golodirsen, Amphotericin B may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Amphotericin B may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[R02AA03, dichlorobenzyl alcohol, Amphotericin B may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Amphotericin B may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Amphotericin B.]
[C08CA16, clevidipine, Clevidipine may decrease the nephrotoxic activities of Amphotericin B.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be decreased when used in combination with Amphotericin B.]
[C02AA06, methoserpidine, Amphotericin B may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Opicapone.]
[N02BA03, choline salicylate, Amphotericin B may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Amphotericin B may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Amphotericin B may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Amphotericin B may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[V04CH02, indigo carmine, Amphotericin B may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[N05CC01, chloral hydrate, Amphotericin B may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[N03AG01, valproic acid, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Amphotericin B.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Amphotericin B.]
[D10AX03, azelaic acid, Amphotericin B may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Fusidic acid.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Amphotericin B.]
[M01AC04, droxicam, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Droxicam.]
[V08CA05, mangafodipir, Amphotericin B may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Amphotericin B.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Dyclonine.]
[C08CA17, levamlodipine, Levamlodipine may decrease the nephrotoxic activities of Amphotericin B.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Amphotericin B.]
[C03AA04, chlorothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Chlorothiazide.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amphotericin B.]
[A10BB02, chlorpropamide, Amphotericin B may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amphotericin B.]
[M03BB03, chlorzoxazone, Amphotericin B may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ethenzamide.]
[N06BX18, vinpocetine, Vinpocetine may decrease the nephrotoxic activities of Amphotericin B.]
[M01AB08, etodolac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etofenamate.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Etofibrate.]
[M01AX25, chondroitin sulfates, Amphotericin B may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Vericiguat.]
[N03AX10, felbamate, The therapeutic efficacy of Felbamate can be decreased when used in combination with Amphotericin B.]
[M01AE05, fenbufen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Fenoldopam.]
[J01DD15, cefdinir, Amphotericin B may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[R03BA03, flunisolide, The risk or severity of hypokalemia can be increased when Flunisolide is combined with Amphotericin B.]
[S02BA08, fluocinolone acetonide, The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Amphotericin B.]
[N02BG07, flupirtine, Amphotericin B may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[H04AA02, dasiglucagon, Amphotericin B may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Amphotericin B.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Amphotericin B.]
[V08CA04, gadoteridol, Amphotericin B may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may decrease the nephrotoxic activities of Amphotericin B.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Amphotericin B.]
[L01XA01, cisplatin, Amphotericin B may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Mefenamic acid.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Amphotericin B.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Clomipramine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Amphotericin B.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Amphotericin B.]
[J05AH02, oseltamivir, Amphotericin B may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[J02AC06, oteseconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Oteseconazole.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Amphotericin B.]
[J01GB12, arbekacin, Amphotericin B may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Cocaine.]
[C02KB01, metyrosine, Amphotericin B may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Proquazone.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Colchicine.]
[J01XB01, colistin, Amphotericin B may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefpirome.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Desflurane.]
[A04AA03, tropisetron, Amphotericin B may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Amphotericin B.]
[A10BX03, nateglinide, Amphotericin B may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Imidazole salicylate.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Amphotericin B.]
[B01AC10, indobufen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Indobufen.]
[J05AB14, valganciclovir, Amphotericin B may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Amphotericin B may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Amphotericin B may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Amphotericin B may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Amphotericin B may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Amphotericin B may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Amphotericin B.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lanatoside C.]
[N02CC05, almotriptan, Amphotericin B may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Parecoxib.]
[J02AC02, itraconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Acyclovir.]
[N05BA10, ketazolam, Amphotericin B may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Kebuzone.]
[J02AC04, posaconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Posaconazole.]
[C08CA09, lacidipine, Amphotericin B may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Amphotericin B.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Amphotericin B.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Amphotericin B.]
[N07BC04, lofexidine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Amphotericin B.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lisinopril.]
[A06AD01, magnesium carbonate, Amphotericin B may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Manidipine may decrease the nephrotoxic activities of Amphotericin B.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Mebeverine.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Amphotericin B.]
[J01DH02, meropenem, Amphotericin B may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C04AX01, cyclandelate, Cyclandelate may decrease the nephrotoxic activities of Amphotericin B.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Eplerenone.]
[N05AD03, metylperon, Amphotericin B may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Amphotericin B.]
[S01XA18, cyclosporine, Amphotericin B may increase the nephrotoxic activities of Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Amphotericin B.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Moexipril.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Amphotericin B.]
[M01AH05, etoricoxib, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etoricoxib.]
[L01AX04, dacarbazine, Amphotericin B may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[C02CC04, debrisoquin, Amphotericin B may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Amphotericin B.]
[M01AX01, nabumetone, The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Amphotericin B.]
[N07BB05, nalmefene, Amphotericin B may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nebivolol.]
[S01GX04, nedocromil, Amphotericin B may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Amphotericin B may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Amphotericin B.]
[L02BB02, nilutamide, Amphotericin B may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The therapeutic efficacy of Tiagabine can be decreased when used in combination with Amphotericin B.]
[M03AC11, cisatracurium, Amphotericin B may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Amphotericin B may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[A07EC03, olsalazine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Olsalazine.]
[N06AA01, desipramine, Amphotericin B may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.]
[H01BA02, desmopressin, Amphotericin B may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Amphotericin B.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Amphotericin B.]
[J01DH03, ertapenem, Amphotericin B may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Amphotericin B.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Amphotericin B.]
[N06BA02, dextroamphetamine, Amphotericin B may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N03AC01, paramethadione, The therapeutic efficacy of Paramethadione can be decreased when used in combination with Amphotericin B.]
[C01DA05, pentaerythritol tetranitrate, Amphotericin B may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Amphotericin B may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Amphotericin B.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be decreased when used in combination with Amphotericin B.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Diazoxide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Phenol.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be decreased when used in combination with Amphotericin B.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Cinchocaine.]
[R05DA08, pholcodine, Amphotericin B may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Amphotericin B.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Foscarnet.]
[A03AA07, dicyclomine, Amphotericin B may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Amphotericin B may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, Amphotericin B may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, Pinaverium may decrease the nephrotoxic activities of Amphotericin B.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Pipamperone.]
[C08CA03, isradipine, Isradipine may decrease the nephrotoxic activities of Amphotericin B.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Amphotericin B.]
[N02BA11, diflunisal, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.]
[C02DB01, dihydralazine, Amphotericin B may increase the hypotensive activities of Dihydralazine.]
[N02AA03, hydromorphone, Amphotericin B may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Amphotericin B may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Atazanavir.]
[B01AC21, treprostinil, Amphotericin B may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Amphotericin B may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Amphotericin B may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Pramocaine.]
[C08DB01, diltiazem, Diltiazem may decrease the nephrotoxic activities of Amphotericin B.]
[V03AB09, dimercaprol, Amphotericin B may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Amphotericin B may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Amphotericin B.]
[N02BB04, propyphenazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Proglumetacin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dipyridamole.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Amphotericin B.]
[S01AX06, resorcinol, Amphotericin B may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Amphotericin B may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N07XX02, riluzole, The therapeutic efficacy of Riluzole can be decreased when used in combination with Amphotericin B.]
[N05AX08, risperidone, Amphotericin B may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Amphotericin B may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Ropivacaine.]
[G04BE08, tadalafil, Amphotericin B may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Amphotericin B.]
[C02KX02, ambrisentan, Amphotericin B may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Amphotericin B may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Amphotericin B may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Amphotericin B may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Amphotericin B may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, Amphotericin B may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01AA02, doxycycline, Amphotericin B may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Sevoflurane.]
[A08AA10, sibutramine, Amphotericin B may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Amphotericin B.]
[A12CA02, sodium sulfate, Amphotericin B may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Amphotericin B may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Amphotericin B may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Amphotericin B may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Amphotericin B may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, Amphotericin B may increase the hypotensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Amphotericin B.]
[L01AX03, temozolomide, Amphotericin B may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Amphotericin B.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Terazosin.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Terbinafine.]
[G04BD05, terodiline, Terodiline may decrease the nephrotoxic activities of Amphotericin B.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Amphotericin B.]
[M01AG02, tolfenamic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Amphotericin B.]
[N06BA09, atomoxetine, Amphotericin B may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Amphotericin B.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Amphotericin B.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Amphotericin B.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Amphotericin B.]
[C02CA06, urapidil, Amphotericin B may increase the hypotensive activities of Urapidil.]
[N06AX16, venlafaxine, Amphotericin B may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[S01GA03, xylometazoline, Xylometazoline may decrease the nephrotoxic activities of Amphotericin B.]
[C08CA12, mepirodipine, Barnidipine may decrease the nephrotoxic activities of Amphotericin B.]
[C09AA15, zofenopril, Amphotericin B may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may decrease the nephrotoxic activities of Amphotericin B.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Carboplatin.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Iloprost.]
[L03AX05, pidotimod, Amphotericin B may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be decreased when used in combination with Amphotericin B.]
[A02BC02, pantoprazole, Amphotericin B may decrease the excretion rate of Pantoprazole which could result in a higher serum level.]
[G03CA03, estradiol, Amphotericin B may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Amphotericin B may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Amphotericin B may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Amphotericin B.]
[R03BA05, fluticasone, The risk or severity of hypokalemia can be increased when Fluticasone is combined with Amphotericin B.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Fluvastatin.]
[V08CA03, gadodiamide, Amphotericin B may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Amifostine.]
[C01BD05, ibutilide, Amphotericin B may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N03AD01, ethosuximide, Ethosuximide may decrease the nephrotoxic activities of Amphotericin B.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be decreased when used in combination with Amphotericin B.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Etidocaine.]
[N01AX07, etomidate, Amphotericin B may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tacrolimus.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Amphotericin B.]
[P01AX07, trimetrexate, Amphotericin B may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Amphotericin B.]
[N06AB08, fluvoxamine, Amphotericin B may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Amphotericin B.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Amphotericin B.]
[M01CB01, gold sodium thiomalate, Amphotericin B may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Amphotericin B may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Amphotericin B may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A16AA01, levocarnitine, Amphotericin B may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, Felodipine may decrease the nephrotoxic activities of Amphotericin B.]
[C08EA01, fendiline, Fendiline may decrease the nephrotoxic activities of Amphotericin B.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Amphotericin B.]
[M01AE04, fenoprofen, The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Amphotericin B.]
[N02AB03, fentanyl, Amphotericin B may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Amphotericin B may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Amphotericin B.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Amphotericin B.]
[N07AX03, cevimeline, Amphotericin B may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Amphotericin B may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Floctafenine.]
[J02AC01, fluconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Fluconazole.]
[J02AX01, flucytosine, Amphotericin B may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Amphotericin B.]
[V03AB25, flumazenil, Amphotericin B may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Amphotericin B.]
[N07CA03, flunarizine, Flunarizine may decrease the nephrotoxic activities of Amphotericin B.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Amphotericin B.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Amphotericin B.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Amphotericin B.]
[L01BC09, floxuridine, Amphotericin B may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[S01CB05, fluorometholone, The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Amphotericin B.]
[N05CD01, flurazepam, Amphotericin B may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Flurbiprofen.]
[N05AG01, fluspirilene, Fluspirilene may decrease the nephrotoxic activities of Amphotericin B.]
[L02BB01, flutamide, Amphotericin B may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Amphotericin B may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Amphotericin B may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Amphotericin B.]
[L01BC03, tegafur, Amphotericin B may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Amphotericin B.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Furosemide.]
[N05CF04, eszopiclone, Amphotericin B may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[C08DA02, gallopamil, Gallopamil may decrease the nephrotoxic activities of Amphotericin B.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Amphotericin B.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Gemfibrozil.]
[J01XA03, telavancin, Amphotericin B may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N03AD03, methsuximide, Methsuximide may decrease the nephrotoxic activities of Amphotericin B.]
[A10BB07, glipizide, Amphotericin B may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amphotericin B.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitroglycerin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Amphotericin B.]
[L01EX02, sorafenib, Amphotericin B may decrease the excretion rate of Sorafenib which could result in a higher serum level.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Amphotericin B.]
[M01CB04, aurothioglucose, Amphotericin B may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Amphotericin B may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Amphotericin B.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Amphotericin B.]
[S01EX01, guanethidine, Amphotericin B may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Amphotericin B may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, Amphotericin B may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Quetiapine.]
[N06BX13, idebenone, Amphotericin B may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Amphotericin B may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Amphotericin B.]
[G03DC01, allylestrenol, Amphotericin B may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Amphotericin B.]
[C01CE02, milrinone, Amphotericin B may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Amphotericin B.]
[C08CA10, nilvadipine, Nilvadipine may decrease the nephrotoxic activities of Amphotericin B.]
[M02AA26, nimesulide, Nimesulide may decrease the nephrotoxic activities of Amphotericin B.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Amphotericin B.]
[C03AA02, hydroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Amphotericin B may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[V03AB33, hydroxocobalamin, Amphotericin B may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Amphotericin B may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Amphotericin B may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[C02AC06, rilmenidine, Amphotericin B may increase the hypotensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ibuprofen.]
[B05XA08, sodium acetate, Amphotericin B may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Amphotericin B may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Amphotericin B.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of hypokalemia can be increased when Tixocortol is combined with Amphotericin B.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Amphotericin B.]
[L01CE01, topotecan, Amphotericin B may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Amphotericin B.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Indoramin.]
[A11HA07, inositol, Amphotericin B may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Amphotericin B may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Amphotericin B may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Articaine.]
[A10BH01, sitagliptin, Amphotericin B may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Amphotericin B may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Amphotericin B may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Amphotericin B.]
[C07AA01, alprenolol, Amphotericin B may increase the hypotensive activities of Alprenolol.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Amphotericin B.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Amphotericin B.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Amphotericin B.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoflurane.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Isoniazid.]
[J05AX05, inosine pranobex, Amphotericin B may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Isotretinoin.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoxsuprine.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Amphotericin B.]
[S01AA24, kanamycin, Amphotericin B may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Amphotericin B.]
[N01AX03, ketamine, Amphotericin B may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, Amphotericin B may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Amphotericin B may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ketoconazole.]
[H02CA04, levoketoconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Amphotericin B.]
[M02AA10, ketoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ketoprofen.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Amphotericin B.]
[N04BB01, amantadine, Amphotericin B may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C02AA05, deserpidine, Amphotericin B may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Amphotericin B.]
[A06AX03, lubiprostone, Amphotericin B may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Amphotericin B.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Amphotericin B is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Lidocaine.]
[C08EX01, lidoflazine, Lidoflazine may decrease the nephrotoxic activities of Amphotericin B.]
[S01AA21, amikacin, Amphotericin B may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Amphotericin B.]
[A07DA03, loperamide, Loperamide may decrease the nephrotoxic activities of Amphotericin B.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Amphotericin B.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Amphotericin B.]
[B05XA11, magnesium chloride, Amphotericin B may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Amphotericin B may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, Magnesium sulfate may decrease the nephrotoxic activities of Amphotericin B.]
[L01BA05, pralatrexate, Amphotericin B may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Amphotericin B.]
[N06AA21, maprotiline, Amphotericin B may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Amphotericin B.]
[M02AA18, meclofenamic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Meclofenamic acid.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be decreased when used in combination with Amphotericin B.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Amphotericin B.]
[N06DX01, memantine, Amphotericin B may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Amphotericin B may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Amphotericin B.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Amphotericin B.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Mepivacaine.]
[G04BX16, tiopronin, Amphotericin B may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Amphotericin B may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AX13, paliperidone, Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, Amphotericin B may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BC02, methadone, Amphotericin B may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Amphotericin B may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Lamivudine.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Amphotericin B.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Methazolamide.]
[H03BB02, methimazole, Amphotericin B may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Amphotericin B may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Amphotericin B.]
[A11HA02, pyridoxine, Amphotericin B may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[N02BG08, ziconotide, Ziconotide may decrease the nephrotoxic activities of Amphotericin B.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Amphotericin B.]
[D05BA02, methoxsalen, Amphotericin B may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Methyclothiazide.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Amphotericin B.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Amphotericin B.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Amphotericin B.]
[N03AF03, rufinamide, The therapeutic efficacy of Rufinamide can be decreased when used in combination with Amphotericin B.]
[G03EK01, methyltestosterone, Amphotericin B may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Amphotericin B.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Amphotericin B.]
[V04CD01, metyrapone, Amphotericin B may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[S02AA13, miconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Aminophenazone.]
[N05CD08, midazolam, Amphotericin B may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[J05AH01, zanamivir, Amphotericin B may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Amphotericin B.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Minocycline.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Amphotericin B.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amphotericin B.]
[C01BD01, amiodarone, Amiodarone may decrease the nephrotoxic activities of Amphotericin B.]
[N06AA09, amitriptyline, Amphotericin B may decrease the excretion rate of Amitriptyline which could result in a higher serum level.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Amphotericin B.]
[A04AA05, palonosetron, Amphotericin B may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Amphotericin B may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Amphotericin B may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Amphotericin B may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Amphotericin B.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Raltegravir.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Amphotericin B.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nadolol.]
[J01CA04, amoxicillin, Amphotericin B may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Amphotericin B.]
[V03AB15, naloxone, Amphotericin B may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Naltrexone.]
[N06BA01, amphetamine, Amphotericin B may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Amphotericin B is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Amphotericin B.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Neomycin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Levosimendan.]
[B01AC17, tirofiban, Amphotericin B may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[S01AA19, ampicillin, Amphotericin B may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Amphotericin B may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Amphotericin B may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Amphotericin B may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Telmisartan.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Amphotericin B.]
[C01CE01, inamrinone, Amphotericin B may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Amphotericin B.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Amphotericin B.]
[C08CA04, nicardipine, Nicardipine may decrease the nephrotoxic activities of Amphotericin B.]
[C08CA05, nifedipine, Nifedipine may decrease the nephrotoxic activities of Amphotericin B.]
[M02AA17, niflumic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may decrease the nephrotoxic activities of Amphotericin B.]
[C08CA07, nisoldipine, Nisoldipine may decrease the nephrotoxic activities of Amphotericin B.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Amphotericin B.]
[C08CA08, nitrendipine, Nitrendipine may decrease the nephrotoxic activities of Amphotericin B.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Amphotericin B.]
[J01XE01, nitrofurantoin, Amphotericin B may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Amphotericin B.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Amphotericin B.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Amphotericin B.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Norfloxacin.]
[C02KX01, bosentan, Amphotericin B may increase the hypotensive activities of Bosentan.]
[G02CA02, nylidrin, Nylidrin may decrease the nephrotoxic activities of Amphotericin B.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ofloxacin.]
[N02AA02, opium, Amphotericin B may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tamsulosin.]
[C01AC01, ouabain, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Zoledronic acid.]
[J01CF04, oxacillin, Amphotericin B may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Amphotericin B may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Oxprenolol.]
[S01BC02, oxyphenbutazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Oxyphenbutazone.]
[J04AB30, capreomycin, Amphotericin B may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Papaverine.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Amphotericin B.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Amphotericin B.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Amphotericin B.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Paromomycin.]
[G04BD11, fesoterodine, Amphotericin B may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Penbutolol.]
[N05AG03, penfluridol, Penfluridol may decrease the nephrotoxic activities of Amphotericin B.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Amphotericin B may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Amphotericin B.]
[L01XX08, pentostatin, Amphotericin B may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Amphotericin B may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[C08EX02, perhexiline, Perhexiline may decrease the nephrotoxic activities of Amphotericin B.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Phenazopyridine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Amphotericin B.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Amphotericin B.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Amphotericin B.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Amphotericin B.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Phenylbutazone.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Amphotericin B.]
[S01AE05, levofloxacin, Amphotericin B may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Amphotericin B may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Amphotericin B.]
[C08CX01, mibefradil, Mibefradil may decrease the nephrotoxic activities of Amphotericin B.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Pindolol.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Atorvastatin.]
[J01CA12, piperacillin, Amphotericin B may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Saquinavir.]
[N06BX03, piracetam, Amphotericin B may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Amphotericin B.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefditoren.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Irbesartan.]
[A10BG02, rosiglitazone, Amphotericin B may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Polythiazide.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Amphotericin B.]
[A10BH03, saxagliptin, Amphotericin B may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Amphotericin B may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Pitavastatin.]
[C07AB01, practolol, Amphotericin B may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Amphotericin B.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Amphotericin B.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Amphotericin B.]
[C01DX02, prenylamine, Prenylamine may decrease the nephrotoxic activities of Amphotericin B.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Prilocaine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Amphotericin B.]
[M04AB01, probenecid, Amphotericin B may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, Amphotericin B may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Procaine.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Amphotericin B.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Fenofibrate.]
[R06AD02, promethazine, Amphotericin B may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[A03AB05, propantheline, Amphotericin B may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Propofol.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Propranolol is combined with Amphotericin B.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Amphotericin B.]
[C01AB01, proscillaridin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Proscillaridin.]
[N02CC04, rizatriptan, Amphotericin B may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Amphotericin B.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Amphotericin B.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Amphotericin B is combined with Dalfampridine.]
[P02CC01, pyrantel, Amphotericin B may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Amphotericin B may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[C01BA01, quinidine, Amphotericin B may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ranitidine.]
[C02AA01, rescinnamine, Amphotericin B may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Amphotericin B.]
[J05AP01, ribavirin, Amphotericin B may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Amphotericin B.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Amphotericin B.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Obinutuzumab.]
[J01GB08, sisomicin, Amphotericin B may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Amphotericin B may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Amphotericin B may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Amphotericin B.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Amphotericin B.]
[S02DA03, antipyrine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Amphotericin B.]
[J01GA01, streptomycin, Amphotericin B may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Amphotericin B may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Amphotericin B may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Amphotericin B may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Amphotericin B.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be decreased when used in combination with Amphotericin B.]
[M01AX04, apazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Azapropazone.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Amphotericin B.]
[N05CD07, temazepam, Amphotericin B may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, Amphotericin B may decrease the excretion rate of Terbutaline which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Amphotericin B may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Amphotericin B may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Tetracaine.]
[S03AA02, tetracycline, Amphotericin B may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftaroline fosamil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Thalidomide.]
[P02CA02, thiabendazole, Amphotericin B may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Amphotericin B may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Amphotericin B.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Amphotericin B.]
[G04BE06, moxisylyte, Amphotericin B may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Amphotericin B may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Amphotericin B may decrease the excretion rate of Ticlopidine which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Amphotericin B.]
[P01AB02, tinidazole, Amphotericin B may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Amphotericin B may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Amphotericin B may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tolazoline.]
[V04CA01, tolbutamide, Amphotericin B may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Amphotericin B.]
[N02AX02, tramadol, Amphotericin B may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Amphotericin B.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Amphotericin B.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Amphotericin B.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Trichlormethiazide.]
[A16AX12, trientine, Amphotericin B may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Amphotericin B may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[D07AC02, fluclorolone, The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Amphotericin B.]
[R03BA07, mometasone, The risk or severity of hypokalemia can be increased when Mometasone is combined with Amphotericin B.]
[A03AA05, trimebutine, Trimebutine may decrease the nephrotoxic activities of Amphotericin B.]
[N03AC02, trimethadione, Trimethadione may decrease the nephrotoxic activities of Amphotericin B.]
[C02BA01, trimethaphan, Amphotericin B may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Amphotericin B.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, Amphotericin B may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Amphotericin B may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Amphotericin B may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[S01AA28, vancomycin, Amphotericin B may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be decreased when used in combination with Amphotericin B.]
[B01AF01, rivaroxaban, Amphotericin B may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, Verapamil may decrease the nephrotoxic activities of Amphotericin B.]
[N06AX09, viloxazine, Amphotericin B may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[C04AX07, vincamine, Amphotericin B may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Amphotericin B.]
[B03BA01, vitamin B12, Amphotericin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Amphotericin B.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Fusidic acid.]
[C03BA10, xipamide, Amphotericin B may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Amphotericin B.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Amphotericin B.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Amphotericin B.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Amphotericin B.]
[M05BA05, tiludronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Tiludronic acid.]
[B06AC02, icatibant, Amphotericin B may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[A02BC04, rabeprazole, Amphotericin B may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Ibandronate.]
[V03AC02, deferiprone, Amphotericin B may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Amphotericin B may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Amphotericin B may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Amphotericin B may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Amphotericin B.]
[J02AC03, voriconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Voriconazole.]
[M01CB03, auranofin, Amphotericin B may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of hypokalemia can be increased when Prednylidene is combined with Amphotericin B.]
[B03XA04, peginesatide, Amphotericin B may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Amphotericin B may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Amphotericin B may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Amphotericin B may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Amphotericin B may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Amphotericin B.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Amphotericin B.]
[M03BX01, baclofen, Amphotericin B may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[A08AA11, lorcaserin, Amphotericin B may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Amphotericin B may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Amphotericin B may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[H02AA01, aldosterone, The risk or severity of hypokalemia can be increased when Aldosterone is combined with Amphotericin B.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Amphotericin B.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin.]
[D02BA02, octinoxate, Amphotericin B may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Amphotericin B.]
[C08CA13, lercanidipine, Lercanidipine may decrease the nephrotoxic activities of Amphotericin B.]
[N03AX22, perampanel, The therapeutic efficacy of Perampanel can be decreased when used in combination with Amphotericin B.]
[V09IX04, fluorodeoxyglucose F18, Amphotericin B may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Amphotericin B.]
[V08CA11, gadofosveset, Amphotericin B may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Amphotericin B may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, Bencyclane may decrease the nephrotoxic activities of Amphotericin B.]
[A10BH04, alogliptin, Amphotericin B may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Amphotericin B may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, Amphotericin B may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Benzocaine.]
[L03AA12, ancestim, Amphotericin B may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Amphotericin B.]
[N04AC01, benztropine, Amphotericin B may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[R02AX03, benzydamine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Benzydamine.]
[L01EE01, trametinib, Amphotericin B may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Amphotericin B may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Amphotericin B may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[C08EA02, bepridil, Bepridil may decrease the nephrotoxic activities of Amphotericin B.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Riociguat.]
[A10BJ03, lixisenatide, Amphotericin B may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Amphotericin B may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Amphotericin B may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Amphotericin B may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Amphotericin B.]
[J05AP08, sofosbuvir, Amphotericin B may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Amphotericin B.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.]
[C01CA27, droxidopa, Amphotericin B may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acebutolol.]
[N05CH03, tasimelteon, Amphotericin B may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Amphotericin B may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Amphotericin B may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of hypokalemia can be increased when Betamethasone is combined with Amphotericin B.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Amphotericin B.]
[V03AB34, fomepizole, Amphotericin B may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Amphotericin B may increase the hypotensive activities of Bethanidine.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Bezafibrate.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Amphotericin B.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.]
[V08AA01, diatrizoic acid, Amphotericin B may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[V08AA04, iothalamic acid, Amphotericin B may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Dihydrostreptomycin.]
[S03AA06, gentamicin, Amphotericin B may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Amphotericin B.]
[B01AF03, edoxaban, Amphotericin B may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N02BE01, acetaminophen, Amphotericin B may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Amphotericin B may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Amphotericin B.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Adefovir dipivoxil.]
[M02AA25, aceclofenac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Amphotericin B.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Acipimox.]
[V03AB37, idarucizumab, Amphotericin B may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Trabectedin.]
[J02AC05, isavuconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Isavuconazole.]
[J05AF13, tenofovir alafenamide, Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Amphotericin B may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Amphotericin B may increase the hypotensive activities of Selexipag.]
[M04AB05, lesinurad, Amphotericin B may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Alminoprofen.]
[N03AX23, brivaracetam, The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Amphotericin B.]
[N05BA08, bromazepam, Amphotericin B may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Amphotericin B may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[C08CA01, amlodipine, Amlodipine may decrease the nephrotoxic activities of Amphotericin B.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Bupivacaine.]
[C07AA19, bupranolol, Amphotericin B may increase the hypotensive activities of Bupranolol.]
[N05BE01, buspirone, Amphotericin B may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Arsenic trioxide.]
[M02AA03, clofezone, Amphotericin B may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Balsalazide.]
[A06AH05, naldemedine, Amphotericin B may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Amphotericin B may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Amphotericin B.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be decreased when used in combination with Amphotericin B.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Amphotericin B.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Amphotericin B may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Amphotericin B.]
[J05AF06, abacavir, Amphotericin B may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Amphotericin B may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Amphotericin B.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Amphotericin B.]
[J01MA23, delafloxacin, Amphotericin B may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[D01AC10, bifonazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Bifonazole.]
[L01BC06, capecitabine, Amphotericin B may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Amphotericin B.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefprozil.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nesiritide.]
[R03BA02, budesonide, The risk or severity of hypokalemia can be increased when Budesonide is combined with Amphotericin B.]
[M01AB07, bumadizone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Bumadizone.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Capsaicin.]
[R06AX18, acrivastine, Amphotericin B may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Captopril.]
[L02BB05, apalutamide, Amphotericin B may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Amphotericin B may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Amphotericin B.]
[C07AG02, carvedilol, Carvedilol may decrease the nephrotoxic activities of Amphotericin B.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Amphotericin B.]
[N03AX24, cannabidiol, The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Amphotericin B.]
[L04AA37, baricitinib, Amphotericin B may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftibuten.]
[J01GB14, plazomicin, Amphotericin B may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Amphotericin B may increase the hypotensive activities of Celiprolol.]
[A16AX14, migalastat, Amphotericin B may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The therapeutic efficacy of Stiripentol can be decreased when used in combination with Amphotericin B.]
[S01GX12, cetirizine, Amphotericin B may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Amphotericin B may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Inotersen.]
[L01AD01, carmustine, Amphotericin B may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Amphotericin B is combined with Amifampridine.]
[A06AX05, prucalopride, Amphotericin B may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilazapril.]
[B01AC23, cilostazol, Amphotericin B may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ciprofibrate.]
[N06BA14, solriamfetol, Amphotericin B may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be decreased when used in combination with Amphotericin B.]
[N05BA09, clobazam, The therapeutic efficacy of Clobazam can be decreased when used in combination with Amphotericin B.]
[H02AB14, cloprednol, The risk or severity of hypokalemia can be increased when Cloprednol is combined with Amphotericin B.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ubidecarenone.]
[C09CA06, candesartan, Amphotericin B may increase the hypotensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hypokalemia can be increased when Cortivazol is combined with Amphotericin B.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefaclor.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefazolin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Amphotericin B.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefonicid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Amphotericin B.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Amphotericin B.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Amphotericin B.]
[C03BX03, cicletanine, Amphotericin B may increase the hypotensive activities of Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefuroxime.]
[N07XX11, pitolisant, Amphotericin B may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Cyclothiazide.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amphotericin B.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Cephalexin is combined with Amphotericin B.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Amphotericin B.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of hypokalemia can be increased when Deflazacort is combined with Amphotericin B.]
[N03AX25, cenobamate, The therapeutic efficacy of Cenobamate can be decreased when used in combination with Amphotericin B.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Givosiran.]
[M09AX08, golodirsen, Amphotericin B may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Amphotericin B may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[R02AA03, dichlorobenzyl alcohol, Amphotericin B may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Amphotericin B may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Amphotericin B.]
[C08CA16, clevidipine, Clevidipine may decrease the nephrotoxic activities of Amphotericin B.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be decreased when used in combination with Amphotericin B.]
[C02AA06, methoserpidine, Amphotericin B may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Amphotericin B.]
[M01AC04, droxicam, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Droxicam.]
[V08CA05, mangafodipir, Amphotericin B may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Amphotericin B.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Dyclonine.]
[C08CA17, levamlodipine, Levamlodipine may decrease the nephrotoxic activities of Amphotericin B.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Amphotericin B.]
[C03AA04, chlorothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Chlorothiazide.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amphotericin B.]
[A10BB02, chlorpropamide, Amphotericin B may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amphotericin B.]
[M03BB03, chlorzoxazone, Amphotericin B may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ethenzamide.]
[N02BA03, choline salicylate, Amphotericin B may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Vinpocetine may decrease the nephrotoxic activities of Amphotericin B.]
[M01AB08, etodolac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etofenamate.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Etofibrate.]
[M01AX25, chondroitin sulfates, Amphotericin B may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Vericiguat.]
[N03AX10, felbamate, The therapeutic efficacy of Felbamate can be decreased when used in combination with Amphotericin B.]
[M01AE05, fenbufen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Fenoldopam.]
[J01DD15, cefdinir, Amphotericin B may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[R03BA03, flunisolide, The risk or severity of hypokalemia can be increased when Flunisolide is combined with Amphotericin B.]
[S02BA08, fluocinolone acetonide, The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Amphotericin B.]
[N02BG07, flupirtine, Amphotericin B may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[H04AA02, dasiglucagon, Amphotericin B may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Amphotericin B.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Amphotericin B.]
[V08CA04, gadoteridol, Amphotericin B may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may decrease the nephrotoxic activities of Amphotericin B.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Amphotericin B.]
[L01XA01, cisplatin, Amphotericin B may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Amphotericin B may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Amphotericin B may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Amphotericin B may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Mefenamic acid.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Amphotericin B.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Clomipramine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Amphotericin B.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Amphotericin B.]
[J05AH02, oseltamivir, Amphotericin B may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[J02AC06, oteseconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Oteseconazole.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Amphotericin B.]
[J01GB12, arbekacin, Amphotericin B may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Cocaine.]
[C02KB01, metyrosine, Amphotericin B may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Proquazone.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Colchicine.]
[J01XB01, colistin, Amphotericin B may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefpirome.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Desflurane.]
[A04AA03, tropisetron, Amphotericin B may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Amphotericin B.]
[A10BX03, nateglinide, Amphotericin B may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Imidazole salicylate.]
[R03BA08, ciclesonide, The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Amphotericin B.]
[B01AC10, indobufen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Indobufen.]
[J05AB14, valganciclovir, Amphotericin B may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Amphotericin B may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Amphotericin B may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Amphotericin B may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Amphotericin B may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Amphotericin B may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Amphotericin B.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lanatoside C.]
[N02CC05, almotriptan, Amphotericin B may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Parecoxib.]
[J02AC02, itraconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Acyclovir.]
[N05BA10, ketazolam, Amphotericin B may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Kebuzone.]
[J02AC04, posaconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Posaconazole.]
[C08CA09, lacidipine, Amphotericin B may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Amphotericin B.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Amphotericin B.]
[S01BA03, cortisone, The risk or severity of hypokalemia can be increased when Cortisone is combined with Amphotericin B.]
[N07BC04, lofexidine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Amphotericin B.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Lisinopril.]
[A06AD01, magnesium carbonate, Amphotericin B may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Manidipine may decrease the nephrotoxic activities of Amphotericin B.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Mebeverine.]
[H02AB15, meprednisone, The risk or severity of hypokalemia can be increased when Meprednisone is combined with Amphotericin B.]
[J01DH02, meropenem, Amphotericin B may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C04AX01, cyclandelate, Cyclandelate may decrease the nephrotoxic activities of Amphotericin B.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Eplerenone.]
[N05AD03, metylperon, Amphotericin B may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Amphotericin B.]
[S01XA18, cyclosporine, Amphotericin B may increase the nephrotoxic activities of Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Amphotericin B.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Moexipril.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Amphotericin B.]
[M01AH05, etoricoxib, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etoricoxib.]
[L01AX04, dacarbazine, Amphotericin B may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[C02CC04, debrisoquin, Amphotericin B may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Amphotericin B.]
[M01AX01, nabumetone, The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Amphotericin B.]
[N07BB05, nalmefene, Amphotericin B may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nebivolol.]
[S01GX04, nedocromil, Amphotericin B may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, Amphotericin B may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Amphotericin B.]
[L02BB02, nilutamide, Amphotericin B may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The therapeutic efficacy of Tiagabine can be decreased when used in combination with Amphotericin B.]
[M03AC11, cisatracurium, Amphotericin B may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Amphotericin B may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[A07EC03, olsalazine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Olsalazine.]
[N06AA01, desipramine, Amphotericin B may decrease the excretion rate of Desipramine which could result in a higher serum level.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.]
[H01BA02, desmopressin, Amphotericin B may decrease the excretion rate of Desmopressin which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Amphotericin B.]
[V04CH02, indigo carmine, Amphotericin B may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of hypokalemia can be increased when Desoxycortone is combined with Amphotericin B.]
[J01DH03, ertapenem, Amphotericin B may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Amphotericin B.]
[S03BA01, dexamethasone, The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Amphotericin B.]
[N06BA02, dextroamphetamine, Amphotericin B may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N03AC01, paramethadione, The therapeutic efficacy of Paramethadione can be decreased when used in combination with Amphotericin B.]
[P03AC04, permethrin, Amphotericin B may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Amphotericin B.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be decreased when used in combination with Amphotericin B.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Diazoxide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Phenol.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be decreased when used in combination with Amphotericin B.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Cinchocaine.]
[R05DA08, pholcodine, Amphotericin B may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Amphotericin B.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Foscarnet.]
[A03AA07, dicyclomine, Amphotericin B may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Amphotericin B may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, Amphotericin B may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, Pinaverium may decrease the nephrotoxic activities of Amphotericin B.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Pipamperone.]
[C08CA03, isradipine, Isradipine may decrease the nephrotoxic activities of Amphotericin B.]
[D07XC04, diflucortolone, The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Amphotericin B.]
[N02BA11, diflunisal, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.]
[C02DB01, dihydralazine, Amphotericin B may increase the hypotensive activities of Dihydralazine.]
[N02AA03, hydromorphone, Amphotericin B may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Amphotericin B may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Atazanavir.]
[B01AC21, treprostinil, Amphotericin B may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Amphotericin B may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Amphotericin B may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Pramocaine.]
[C08DB01, diltiazem, Diltiazem may decrease the nephrotoxic activities of Amphotericin B.]
[V03AB09, dimercaprol, Amphotericin B may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Amphotericin B may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Amphotericin B.]
[N02BB04, propyphenazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Proglumetacin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dipyridamole.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Amphotericin B.]
[S01AX06, resorcinol, Amphotericin B may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Amphotericin B may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[N07XX02, riluzole, The therapeutic efficacy of Riluzole can be decreased when used in combination with Amphotericin B.]
[N05AX08, risperidone, Amphotericin B may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Amphotericin B may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Ropivacaine.]
[G04BE08, tadalafil, Amphotericin B may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Amphotericin B.]
[C02KX02, ambrisentan, Amphotericin B may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Amphotericin B may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Amphotericin B may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, Amphotericin B may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[C01CA04, dopamine, Amphotericin B may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA12, doxepin, Amphotericin B may decrease the excretion rate of Doxepin which could result in a higher serum level.]
[J01AA02, doxycycline, Amphotericin B may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Sevoflurane.]
[A08AA10, sibutramine, Amphotericin B may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Amphotericin B.]
[A12CA02, sodium sulfate, Amphotericin B may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Amphotericin B may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Amphotericin B may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, Amphotericin B may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Amphotericin B may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, Amphotericin B may increase the hypotensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of hypokalemia can be increased when Corticotropin is combined with Amphotericin B.]
[L01AX03, temozolomide, Amphotericin B may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Amphotericin B.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Terazosin.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Terbinafine.]
[G04BD05, terodiline, Terodiline may decrease the nephrotoxic activities of Amphotericin B.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Amphotericin B.]
[M01AG02, tolfenamic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Amphotericin B.]
[N06BA09, atomoxetine, Amphotericin B may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Amphotericin B.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Amphotericin B.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Amphotericin B.]
[N05CC01, chloral hydrate, Amphotericin B may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[H02CA01, trilostane, The risk or severity of hypokalemia can be increased when Trilostane is combined with Amphotericin B.]
[C02CA06, urapidil, Amphotericin B may increase the hypotensive activities of Urapidil.]
[N06AX16, venlafaxine, Amphotericin B may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[S01GA03, xylometazoline, Xylometazoline may decrease the nephrotoxic activities of Amphotericin B.]
[C08CA12, mepirodipine, Barnidipine may decrease the nephrotoxic activities of Amphotericin B.]
[C09AA15, zofenopril, Amphotericin B may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may decrease the nephrotoxic activities of Amphotericin B.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Carboplatin.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Iloprost.]
[N03AG01, valproic acid, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Amphotericin B.]
[L03AX05, pidotimod, Amphotericin B may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be decreased when used in combination with Amphotericin B.]
[A02BC02, pantoprazole, Amphotericin B may decrease the excretion rate of Pantoprazole which could result in a higher serum level.]
[G03CA03, estradiol, Amphotericin B may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Amphotericin B may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Amphotericin B may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Amphotericin B.]
[R03BA05, fluticasone, The risk or severity of hypokalemia can be increased when Fluticasone is combined with Amphotericin B.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Fluvastatin.]
[V08CA03, gadodiamide, Amphotericin B may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Amifostine.]
[C01BD05, ibutilide, Amphotericin B may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N03AD01, ethosuximide, Ethosuximide may decrease the nephrotoxic activities of Amphotericin B.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be decreased when used in combination with Amphotericin B.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Etidocaine.]
[N01AX07, etomidate, Amphotericin B may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tacrolimus.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Amphotericin B.]
[P01AX07, trimetrexate, Amphotericin B may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Amphotericin B.]
[N06AB08, fluvoxamine, Amphotericin B may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Amphotericin B.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Amphotericin B.]
[M01CB01, gold sodium thiomalate, Amphotericin B may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Amphotericin B may decrease the excretion rate of Dextran which could result in a higher serum level.]
[M05BA01, etidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Etidronic acid.]
[V03AF02, dexrazoxane, Amphotericin B may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A16AA01, levocarnitine, Amphotericin B may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, Felodipine may decrease the nephrotoxic activities of Amphotericin B.]
[C08EA01, fendiline, Fendiline may decrease the nephrotoxic activities of Amphotericin B.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Amphotericin B.]
[M01AE04, fenoprofen, The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Amphotericin B.]
[N02AB03, fentanyl, Amphotericin B may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Amphotericin B may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Amphotericin B.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Amphotericin B.]
[N07AX03, cevimeline, Amphotericin B may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Amphotericin B may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Floctafenine.]
[J02AC01, fluconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Fluconazole.]
[J02AX01, flucytosine, Amphotericin B may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Amphotericin B.]
[V03AB25, flumazenil, Amphotericin B may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of hypokalemia can be increased when Flumethasone is combined with Amphotericin B.]
[N07CA03, flunarizine, Flunarizine may decrease the nephrotoxic activities of Amphotericin B.]
[D07AC08, fluocinonide, The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Amphotericin B.]
[H02AB03, fluocortolone, The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Amphotericin B.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Amphotericin B.]
[L01BC09, floxuridine, Amphotericin B may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[S01CB05, fluorometholone, The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Amphotericin B.]
[N05CD01, flurazepam, Amphotericin B may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Flurbiprofen.]
[N05AG01, fluspirilene, Fluspirilene may decrease the nephrotoxic activities of Amphotericin B.]
[L02BB01, flutamide, Amphotericin B may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Amphotericin B may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Amphotericin B may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Framycetin is combined with Amphotericin B.]
[L01BC03, tegafur, Amphotericin B may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Amphotericin B.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Furosemide.]
[M05BA04, alendronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Alendronic acid.]
[N05CF04, eszopiclone, Amphotericin B may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[C08DA02, gallopamil, Gallopamil may decrease the nephrotoxic activities of Amphotericin B.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Amphotericin B.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Gemfibrozil.]
[J01XA03, telavancin, Amphotericin B may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N03AD03, methsuximide, Methsuximide may decrease the nephrotoxic activities of Amphotericin B.]
[A10BB07, glipizide, Amphotericin B may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amphotericin B.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitroglycerin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Amphotericin B.]
[L01EX02, sorafenib, Amphotericin B may decrease the excretion rate of Sorafenib which could result in a higher serum level.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Amphotericin B.]
[M01CB04, aurothioglucose, Amphotericin B may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Amphotericin B may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Amphotericin B.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Amphotericin B.]
[S01EX01, guanethidine, Amphotericin B may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Amphotericin B may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, Amphotericin B may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Quetiapine.]
[N06BX13, idebenone, Amphotericin B may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Amphotericin B may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Amphotericin B.]
[G03DC01, allylestrenol, Amphotericin B may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Amphotericin B.]
[C01CE02, milrinone, Amphotericin B may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Amphotericin B.]
[C08CA10, nilvadipine, Nilvadipine may decrease the nephrotoxic activities of Amphotericin B.]
[M02AA26, nimesulide, Nimesulide may decrease the nephrotoxic activities of Amphotericin B.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Amphotericin B.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Amphotericin B.]
[C03AA02, hydroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Amphotericin B may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[V03AB33, hydroxocobalamin, Amphotericin B may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, Amphotericin B may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Amphotericin B may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[C02AC06, rilmenidine, Amphotericin B may increase the hypotensive activities of Rilmenidine.]
[M05BA07, risedronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ibuprofen.]
[B05XA08, sodium acetate, Amphotericin B may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Amphotericin B may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Amphotericin B.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of hypokalemia can be increased when Tixocortol is combined with Amphotericin B.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Amphotericin B.]
[L01CE01, topotecan, Amphotericin B may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Indapamide.]
[S01BC01, indomethacin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Amphotericin B.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Indoramin.]
[A11HA07, inositol, Amphotericin B may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Amphotericin B may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Amphotericin B may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Articaine.]
[A10BH01, sitagliptin, Amphotericin B may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Amphotericin B may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Amphotericin B may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Amphotericin B.]
[C07AA01, alprenolol, Amphotericin B may increase the hypotensive activities of Alprenolol.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Amphotericin B.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Amphotericin B.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Amphotericin B.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoflurane.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Isoniazid.]
[J05AX05, inosine pranobex, Amphotericin B may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Isotretinoin.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Isoxsuprine.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Amphotericin B.]
[S01AA24, kanamycin, Amphotericin B may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Amphotericin B.]
[N01AX03, ketamine, Amphotericin B may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, Amphotericin B may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Amphotericin B may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ketoconazole.]
[H02CA04, levoketoconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Amphotericin B.]
[M02AA10, ketoprofen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ketoprofen.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Rotigotine.]
[D10AX03, azelaic acid, Amphotericin B may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Amphotericin B.]
[N04BB01, amantadine, Amphotericin B may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C02AA05, deserpidine, Amphotericin B may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Amphotericin B.]
[A06AX03, lubiprostone, Amphotericin B may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Amphotericin B.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Amphotericin B is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Lidocaine.]
[C08EX01, lidoflazine, Lidoflazine may decrease the nephrotoxic activities of Amphotericin B.]
[S01AA21, amikacin, Amphotericin B may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Amphotericin B.]
[A07DA03, loperamide, Loperamide may decrease the nephrotoxic activities of Amphotericin B.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Amphotericin B.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Amphotericin B.]
[B05XA11, magnesium chloride, Amphotericin B may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Amphotericin B may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, Magnesium sulfate may decrease the nephrotoxic activities of Amphotericin B.]
[L01BA05, pralatrexate, Amphotericin B may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Amphotericin B.]
[N06AA21, maprotiline, Amphotericin B may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Amphotericin B.]
[M02AA18, meclofenamic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Meclofenamic acid.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be decreased when used in combination with Amphotericin B.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Amphotericin B.]
[N06DX01, memantine, Amphotericin B may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Amphotericin B may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Amphotericin B.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Amphotericin B.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Mepivacaine.]
[G04BX16, tiopronin, Amphotericin B may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Amphotericin B may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AX13, paliperidone, Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[A10BA02, metformin, Amphotericin B may decrease the excretion rate of Metformin which could result in a higher serum level.]
[N07BC02, methadone, Amphotericin B may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, Amphotericin B may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Lamivudine.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Amphotericin B.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Methazolamide.]
[H03BB02, methimazole, Amphotericin B may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Amphotericin B may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Amphotericin B.]
[A11HA02, pyridoxine, Amphotericin B may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[N02BG08, ziconotide, Ziconotide may decrease the nephrotoxic activities of Amphotericin B.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity can be increased when Methotrexate is combined with Amphotericin B.]
[D05BA02, methoxsalen, Amphotericin B may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Methyclothiazide.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Amphotericin B.]
[H02AB04, methylprednisolone, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Amphotericin B.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Amphotericin B.]
[N03AF03, rufinamide, The therapeutic efficacy of Rufinamide can be decreased when used in combination with Amphotericin B.]
[G03EK01, methyltestosterone, Amphotericin B may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Amphotericin B.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Amphotericin B.]
[V04CD01, metyrapone, Amphotericin B may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[S02AA13, miconazole, The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Aminophenazone.]
[N05CD08, midazolam, Amphotericin B may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[J05AH01, zanamivir, Amphotericin B may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Amphotericin B.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Minocycline.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Amphotericin B.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amphotericin B.]
[C01BD01, amiodarone, Amiodarone may decrease the nephrotoxic activities of Amphotericin B.]
[N06AA09, amitriptyline, Amphotericin B may decrease the excretion rate of Amitriptyline which could result in a higher serum level.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Amphotericin B.]
[A04AA05, palonosetron, Amphotericin B may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Amphotericin B may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Amphotericin B may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Amphotericin B may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Amphotericin B.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Raltegravir.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Amphotericin B.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nadolol.]
[J01CA04, amoxicillin, Amphotericin B may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Amphotericin B.]
[V03AB15, naloxone, Amphotericin B may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Naltrexone.]
[N06BA01, amphetamine, Amphotericin B may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Amphotericin B is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Amphotericin B.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Neomycin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Levosimendan.]
[B01AC17, tirofiban, Amphotericin B may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Amphotericin B may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[S01AA19, ampicillin, Amphotericin B may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Amphotericin B may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Amphotericin B may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Amphotericin B may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Telmisartan.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Amphotericin B.]
[C01CE01, inamrinone, Amphotericin B may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Amphotericin B.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Amphotericin B.]
[C08CA04, nicardipine, Nicardipine may decrease the nephrotoxic activities of Amphotericin B.]
[C08CA05, nifedipine, Nifedipine may decrease the nephrotoxic activities of Amphotericin B.]
[M02AA17, niflumic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may decrease the nephrotoxic activities of Amphotericin B.]
[C08CA07, nisoldipine, Nisoldipine may decrease the nephrotoxic activities of Amphotericin B.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Amphotericin B.]
[C08CA08, nitrendipine, Nitrendipine may decrease the nephrotoxic activities of Amphotericin B.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Amphotericin B.]
[J01XE01, nitrofurantoin, Amphotericin B may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Amphotericin B.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Amphotericin B.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Amphotericin B.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Norfloxacin.]
[C02KX01, bosentan, Amphotericin B may increase the hypotensive activities of Bosentan.]
[G02CA02, nylidrin, Nylidrin may decrease the nephrotoxic activities of Amphotericin B.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ofloxacin.]
[N02AA02, opium, Amphotericin B may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Tamsulosin.]
[C01AC01, ouabain, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.]
[M05BA08, zoledronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Zoledronic acid.]
[J01CF04, oxacillin, Amphotericin B may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Amphotericin B may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Oxprenolol.]
[S01BC02, oxyphenbutazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Oxyphenbutazone.]
[J04AB30, capreomycin, Amphotericin B may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Papaverine.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Amphotericin B.]
[H02AB05, paramethasone, The risk or severity of hypokalemia can be increased when Paramethasone is combined with Amphotericin B.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Amphotericin B.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Paromomycin.]
[G04BD11, fesoterodine, Amphotericin B may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Penbutolol.]
[N05AG03, penfluridol, Penfluridol may decrease the nephrotoxic activities of Amphotericin B.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Penicillamine.]
[J01CE09, penicillin G procaine, Amphotericin B may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Amphotericin B.]
[L01XX08, pentostatin, Amphotericin B may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Amphotericin B may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[C08EX02, perhexiline, Perhexiline may decrease the nephrotoxic activities of Amphotericin B.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Phenazopyridine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Amphotericin B.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Amphotericin B.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Amphotericin B.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Amphotericin B.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Phenylbutazone.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Amphotericin B.]
[S01AE05, levofloxacin, Amphotericin B may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Amphotericin B may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Amphotericin B.]
[C08CX01, mibefradil, Mibefradil may decrease the nephrotoxic activities of Amphotericin B.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Pindolol.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Atorvastatin.]
[J01CA12, piperacillin, Amphotericin B may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Saquinavir.]
[N06BX03, piracetam, Amphotericin B may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Amphotericin B.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefditoren.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Irbesartan.]
[A10BG02, rosiglitazone, Amphotericin B may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Polymyxin B.]
[C03AA05, polythiazide, The risk or severity of electrolyte imbalance can be increased when Amphotericin B is combined with Polythiazide.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Amphotericin B.]
[A10BH03, saxagliptin, Amphotericin B may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Amphotericin B may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Pitavastatin.]
[C07AB01, practolol, Amphotericin B may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Amphotericin B.]
[S03BA02, prednisolone, The risk or severity of hypokalemia can be increased when Prednisolone is combined with Amphotericin B.]
[H02AB07, prednisone, The risk or severity of hypokalemia can be increased when Prednisone is combined with Amphotericin B.]
[C01DX02, prenylamine, Prenylamine may decrease the nephrotoxic activities of Amphotericin B.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Prilocaine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Amphotericin B.]
[M04AB01, probenecid, Amphotericin B may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, Amphotericin B may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Procaine.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Amphotericin B.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Fenofibrate.]
[R06AD02, promethazine, Amphotericin B may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[A03AB05, propantheline, Amphotericin B may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Propofol.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Propranolol is combined with Amphotericin B.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Amphotericin B.]
[C01AB01, proscillaridin, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Proscillaridin.]
[N02CC04, rizatriptan, Amphotericin B may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Amphotericin B.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Amphotericin B.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Amphotericin B is combined with Dalfampridine.]
[P02CC01, pyrantel, Amphotericin B may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Amphotericin B may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[C01BA01, quinidine, Amphotericin B may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Ranitidine.]
[C02AA01, rescinnamine, Amphotericin B may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Amphotericin B.]
[J05AP01, ribavirin, Amphotericin B may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[N02BA05, salicylamide, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Amphotericin B.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Amphotericin B.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Obinutuzumab.]
[J01GB08, sisomicin, Amphotericin B may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Amphotericin B may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Amphotericin B may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Amphotericin B.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Amphotericin B.]
